TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03920839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: INCMGA00012 administered intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: INCMGA00012 administered intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: INCMGA00012 administered intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: INCMGA00012 administered intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered intravenously on Days 1 and 8 of 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered intravenously on Day 1 of 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered intravenously on Day 1 of 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed administered intravenously on Day 1 of 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed administered intravenously on Day 1 of 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC5 or AUC6 administered intravenously on Day 1 of 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC5 or AUC6 administered intravenously on Day 1 of 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered intravenously on Day 1 of 21-day cycles.
Study: NCT02946554

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HepaStem

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HepaStem
Study: NCT02935127

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Absorbable suture
Description: Vascular anastomoses will be performed with absorbable materials
Study: NCT03767673

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Final Spirometry
Description: Determination of Vital Capacity by spirometry after (within 30 minutes) spiroergometry. Measurements will be performed in both groups.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Final Spirometry
Description: Determination of Vital Capacity by spirometry after (within 30 minutes) spiroergometry. Measurements will be performed in both groups.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary microbiome (16S rDNA profiling)
Description: Harvesting of deep induced sputum and determination of the airway microbiome by 16S ribosomal RNA (rRNA) pyrosequencing. Evaluation of alpha and beta diversity and relative bacterial abundance at the genus level. Measurements will be performed in both groups (samples will be harvested within 30 minutes after spiroergometry).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulmonary microbiome (16S rDNA profiling)
Description: Harvesting of deep induced sputum and determination of the airway microbiome by 16S ribosomal RNA (rRNA) pyrosequencing. Evaluation of alpha and beta diversity and relative bacterial abundance at the genus level. Measurements will be performed in both groups (samples will be harvested within 30 minutes after spiroergometry).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Maximum oxygen uptake
Description: Determination of the maximum oxygen uptake (ml/kg/min) corrected for gender, age and body weight by bicycle spiroergometry. Measurements will be performed in both groups.
Study: NCT01038128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Drug: Memantine, 10-40 mg daily
Study: NCT03761849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7234292
Description: Intrathecal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7234292
Description: Intrathecal injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intrathecal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intrathecal injection
Study: NCT03727334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Spatial Navigation Training
Description: Participants complete training tasks that test their spatial navigational abilities, cognitive map formation, and pattern separation. These training tasks involve map drawing, vector mapping, proximity judgments, and navigating with blocked routes.
Study: NCT00965302

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy, also known as vertical sleeve gastrectomy, sleeve gastroplasty, or sleeve gastrectomy, will be performed over a 32 to 40 French sizing bougie.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive medical management
Description: Intensive medical therapy for Diabetes mellitus, Type 2, will include weight management counseling, exercise, glucose control, and healthy dietary choices.
Study: NCT03427645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision tool
Description: A tailored web-based stroke decision support intervention. This web-based tool will be developed for use by the surrogate decision maker during the acute stroke hospitalization and will be designed to facilitate high quality patient-centered decisions and minimize adverse effects on the surrogate.
Study: NCT00489697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-time contrast-enhanced ultrasound imaging (CEUS)
Description: Real time contrast enhanced sonography was performed using an ultrasound dedicated system after bolus injection of 1.2 and 2x2.4 ml Sonovue ® (Bracco, Milan, Italy)
Study: NCT03886688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC53856
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC53856
Description: oral administration
Study: NCT03767673

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Maximum oxygen uptake
Description: Determination of the maximum oxygen uptake (ml/kg/min) corrected for gender, age and body weight by bicycle spiroergometry. Measurements will be performed in both groups.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Maximum performance
Description: Determination of the maximum performance (W/kg) corrected for body weight by bicycle spiroergometry. Measurements will be performed in both groups.
Study: NCT03886688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC53856
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral administration
Study: NCT03767673

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Maximum performance
Description: Determination of the maximum performance (W/kg) corrected for body weight by bicycle spiroergometry. Measurements will be performed in both groups.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: weight
Description: Determined by Kilogram on a medical weight scale

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: weight
Description: Determined by Kilogram on a medical weight scale

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: age
Description: Determination of age by patient's Report and past medical history
Study: NCT03886688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral administration
Study: NCT01108081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Moderate-intensity physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Dietary weight loss
Study: NCT02165696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal treatment: compression bandaging and manual lymph drainage.
Description: 30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual lymph drainage
Description: 30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
Study: NCT03767673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: age
Description: Determination of age by patient's Report and past medical history
Study: NCT02341963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Ketamine
Description: Oral ketamine (Ketamine HCL injection, 100 mg/ml, USP, Hospira)
Study: NCT03640000

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Impedance measurements in Cardiac Resynchronization therapy
Description: Bioimpedance measurements
Study: NCT02935127

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Absorbable suture
Description: Vascular anastomoses will be performed with non-absorbable materials
Study: NCT02655536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus erlotinib
Description: Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of every 3 weeks cycle by IV infusion erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
Study: NCT03993626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXD101 in Combination With Nivolumab
Description: HDAC inhibitor in combination with anti-PD-1 monoclonal antibody
Study: NCT03458585

Intervention type: OTHER
Intervention: Self-administered questionnaire
Description: Self-administered questionnaire

Intervention type: OTHER
Intervention: Self-administered questionnaire
Description: Self-administered questionnaire
Study: NCT03035383

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Purse string technique
Description: Thyroidectomy closure is performed using purse string suturing technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional technique
Description: Thyroidectomy closure is performed using conventional suturing technique.
Study: NCT04948502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SaExten vena cava filter system
Description: Subjects will undergo intervention, be implanted with a SaExten filter. The filter will be retrieved within 90 days or indwelled permanently, depending on the existence of thrombosis and the evaluation of the physician.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Denali inferior vena cava filter
Description: Subjects will undergo intervention, be implanted with a Denali filter. The filter will be retrieved within 90 days or indwelled permanently, depending on the existence of thrombosis and the evaluation of the physician.
Study: NCT03503669

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory Training
Description: Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kundalini yoga and meditation
Description: Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan Kriya meditation (12 minute duration) for 12 weeks.
Study: NCT01353599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: 220mcg once daily, for eight weeks
Study: NCT03825939

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Description: IV 0.9% sterile saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Placebo
Description: IV 0.9% sterile saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic Acid
Description: 1g TXA IVPB (intravenous piggyback)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Tranexamic Acid
Description: 1g TXA IVPB (intravenous piggyback)
Study: NCT01108081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Dietary weight loss

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Attention control intervention
Study: NCT02911948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide
Description: Injected s.c. / subcutaneously (under the skin) once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec
Description: Injected s.c. / subcutaneously (under the skin) once daily
Study: NCT03277222

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IN insulin
Description: IN insulin twice daily taken after breakfast and again after dinner using the nasal delivery device.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline placebo
Description: Sterile Saline placebo twice daily taken after breakfast and again after dinner using the nasal delivery device.
Study: NCT03726827

Intervention type: OTHER
Intervention: Fibroscan screening
Description: A single Fibroscan screening for fat content and liver stiffness
Study: NCT04399798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: 4 mg/day for 7 days
Study: NCT01311310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RIPC (remote ischemic preconditioning)
Description: RIPC will be performed by four 5-min cycles of lower limb ischemia and 5 in reperfusion using blood-pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure measured via arterial line.
Study: NCT01760694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Modality; IORT, Surgery, Radiation, Chemotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Modality; IORT, Surgery, Radiation, Chemotherapy
Study: NCT03086668

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Jaw thrust Group
Description: a video-stylet assisted nasotracheal intubation and facilitate by conventional jaw thrust technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fingers hook Group
Description: a video-stylet assisted nasotracheal intubation and facilitate by fingers-hook technique
Study: NCT04302428

Intervention type: BIOLOGICAL
Intervention: Serum Zn
Description: The investigators will obtain an additional 2 mL of blood in an extra tube. This will be collected at the same time blood is collected for the participant's yearly CF screening labs so as to minimize additional needle sticks.

Intervention type: BIOLOGICAL
Intervention: Red Blood Cell Zn
Description: If the participant is greater or equal than 5 kg, an additional 2 mL of blood will be obtained in an extra tube. This will be collected at the same time blood is collected for the participant's yearly CF screening labs so as to minimize additional needle sticks.
Study: NCT00871728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole (ICZ) capsule will be administered in 3 cycles (Week 1, Week 5 and Week 9) and each cycle will consist of taking 2 capsules of 100 milligram (mg) each, orally twice daily, continuously for 1 week and then not taking medication for next 3 weeks. Total duration of treatment will be 49 weeks.
Study: NCT01619085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib twice a day
Study: NCT03788798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient infotainment system
Description: The patient infotainment system is a quasi-interactive computer program connected to a server that pushes messages and educational programs ordered from the caring physicians or on-demand by the patients. The server has parallel data exchange gateways to the Hospital Information System (HIS), Picture Archiving Communication System (PACS), and can record the patients' responses to surveys and questionnaires.
Study: NCT01086735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor lymphocyte infusion
Description: Donor T-cell transduction
Study: NCT03143088

Intervention type: BEHAVIORAL
Intervention: Medical clown
Description: Blood pressure will be taken to children admitted to the pediatric emergency department with and without the presence of a medical clown.
Study: NCT02387307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rSIFN-co
Description: rSIFN-co is a drug developed by Sichuan Huiyang Life Science and Technology Corporation for the treatment of solid tumors especially in non-small cell lung cancer and other tumor types. The study comprises of 2 stages: the dose-escalation stage and dose expansion stage.
Study: NCT04399720

Intervention type: PROCEDURE
Intervention: Root canal treatment
Description: Root canal treatment using a standard manual k file instrumentation and carrier-based root canal filling technique

Intervention type: PROCEDURE
Intervention: Root canal treatment
Description: Root canal treatment using a standard manual k file instrumentation and carrier-based root canal filling technique
Study: NCT00729365

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: ACE inhibitor known as Ramipril~Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into this group and given an ACE inhibitor (study medication). Therefore, the Non-Dippers groups II and III will be randomized to receive either drug or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dippers (category of subjects with a nighttime dip in blood pressure) will all be given Placebo. Control group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into the control group and given Placebo.
Study: NCT03909568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Third molar surgery
Description: Comparing complete removal of third molar with removal of crown only on contralateral side
Study: NCT00869089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-10004
Description: 30mg,oral medication, BID, for 24 weeks (60mg total DAILY)
Study: NCT00676026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem 10 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone 800 mg by mouth will be administered to each participant once in the follicular and luteal phases of the menstrual cycle.
Study: NCT00204932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conjugated linoleic acid
Description: 4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA, and 22% safflower oil for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: conjugated linoleic acid
Description: 4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA, and 22% safflower oil for 6 months
Study: NCT04071626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin 5 mg once a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet once a day for 12 weeks
Study: NCT00333073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bulkamid
Description: initial injection with option for second (if required)
Study: NCT02282111

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22-gauge Procore needle (ProCore, Cook Medical Inc., Winston-Salem, NC)
Description: Using a linear EUS with color and pulsed Doppler to scan the area for vessels, the lesion was then sampled with a 22-gauge beveled needle (using the slow capillary suction and fanning techniques with 5 to 15 to-and-fro movements with each pass). A total of 4 passes were performed and after that, the procedure terminated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional needle-knife sphincterotome (Microknife XL; Boston Scientific Inc, Natick, Mass)
Description: Using a conventional needle-knife sphincterotome connected to an electrosurgical unit, and under direct endoscopic vision, a 6-12mm linear incision was made from the periphery of the lesion to its highest convexity zone. A conventional biopsy forceps was then deeply introduced through the hole, and 2 bites were obtained per pass. A total of 4 passes were performed by passing the biopsy forceps through the incision on each occasion. The mucosal incision was then closed with endoclips whenever possible.
Study: NCT00406432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine Controlled Release Tablet
Description: Eligible subjects will receive paroxetine controlled release tablet with dose of 25 milligrams.
Study: NCT02116413

Intervention type: PROCEDURE
Intervention: Fluid challenge
Description: The fluid challenge starts at minute 0 (T0) and consists of 500ml of crystalloids over 10 minutes.

Intervention type: PROCEDURE
Intervention: Cardiac ultrasound
Description: Ultrasound measures are made at T0, T2, T4, T6, T8, T10, T20 and T30.
Study: NCT04821492

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-Energy X-ray Absorptiometry (DXA)
Description: BMD expressed in absolute values as g/cm2 and T-scores

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-Energy X-ray Absorptiometry (DXA)
Description: BMD expressed in absolute values as g/cm2 and T-scores
Study: NCT02050607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation from healthy lean donors
Description: fecal microbiota transplantation from healthy lean donors
Study: NCT01704235

Intervention type: OTHER
Intervention: Demographic Form and Semi-Structured Interview Guide
Description: The demographic form will include the following items: age, age at immigration, years lived in the United States, Vietnamese speaking ability, and marital status. In addition for participants who are primary health care providers, the following items will be included: annual income before taxes, gender, race and ethnicity, specialty area of practice, and number of years practicing as a primary health care provider, practice setting, and country received Pap test training.~A semi-structured interview guide will also be used and will include possible probing questions. A semi-structured interview guide was developed with the research team.